The team’s findings suggest that antibodies that block CD24 and Siglec10 interactions can enhance macrophages’ effectiveness in killing tumor cells in refractory ovarian cancer, which is common in women, and triple-negative breast cancer, which is difficult to immunotherapy. The gene discussed is CD24; the disease is neoplasm.